Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

109.19 -1.89 (-1.70%)
Official Closing Price Updated: 7:00 PM EST, Dec 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,621,740
Open 111.55
Bid (Size) 109.26 (2)
Ask (Size) 110.35 (2)
Prev. Close 111.08
Today's Range 108.70 - 111.55
52wk Range 94.73 - 148.15
Shares Outstanding N/A
Dividend Yield 0.94%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Jim Cramer Is 'Not A Fan' Of Novavax, Says This Tech Stock Is 'Expensive'
Via Benzinga
Warning: This Skyrocketing Stock Has a Hidden Risk
Via The Motley Fool

Performance

YTD
+6.93%
+6.93%
1 Month
+0.09%
+0.09%
3 Month
-15.87%
-15.87%
6 Month
-22.99%
-22.99%
1 Year
+12.97%
+12.97%

More News

Read More
Eli Lilly Stock Just Got Even Sweeter. Here's Why It's Worth Buying Now
Via The Motley Fool
Deal Dispatch: Ubisoft In Buyout Talks, Dental Supplier Explores Sale, Beloved Drive-Through Goes Bankrupt
Via Benzinga
Topics Supply Chain
Exposures Supply Chain
Despite its growth, NYSE:NVO remains within the realm of affordability.
Via Chartmill
3 No-Brainer Growth Stocks to Buy in December
Via The Motley Fool
Could Eli Lilly Beat Rivals in the Billion-Dollar Weight Loss Drug Market in 2025? Evidence Is Piling Up, and Here's What It Says.
Via The Motley Fool
Stock Market Hits Highs On Salesforce, Tech Earnings; Bitcoin Tops $100,000, Briefly: Weekly Review
Via Investor's Business Daily
Amgen Stock Falls on Weight Loss Drug Data: Overreaction or Fair?
Via MarketBeat
How Much Did Americans Overspend On Weight Loss Medications in 2024? GoodRx Reveals
Via Benzinga
2 Telehealth Stocks That Could Gain from Trump’s New FDA Pick
Via MarketBeat
Topics Government Lawsuit
Exposures Financial Legal Political
The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market
Via Investor's Business Daily
This Healthcare Stock Is a Favorite of Billionaires. But Is It a Buy?
Via The Motley Fool
Lilly Tops Nordisk In Weight Loss Battle
Via Talk Markets
Topics Stocks / Equities
Wegovy Maker Novo Nordisk To Buy Novavax's Czech Republic Manufacturing Facility For $200 Million
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Stock Of The Day: Where Will The Eli Lilly Rally End?
Via Benzinga
Eli Lilly's Zepbound Vs. Novo Nordisk's Wegovy - Which Shows Greater Weight Loss?
Via Benzinga
Eli Lilly's Zepbound Beats Novo Nordisk's Wegovy In Head-To-Head Weight-Loss Trial
Via Investor's Business Daily
Eli Lilly Just Got a Bundle of Good News: Time to Buy?
Via The Motley Fool
Weight Loss Drug Wars Heat Up: Amgen Challenges Eli Lilly, Novo's Dominance
Via Benzinga
Want To Bet On Ozempic, Wegovy Success? Defiance Introduces Leveraged ETF To Capture Novo Nordisk Momentum
Via Benzinga
Topics ETFs
Technical Monday: Novo Nordisk, A Love Story
Via Talk Markets
Topics Stocks / Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Big Pharma Pushes To Revise Biden-era Medicare Drug Price Negotiation Law Under Trump
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.